Noveome Biotherapeutics, formerly Stemnion
13
1
1
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
23.1%
3 terminated/withdrawn out of 13 trials
75.0%
-11.5% vs industry average
0%
0 trials in Phase 3/4
22%
2 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis (NEC)
Role: lead
Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis
Role: lead
ST266 Eyedrops for the Treatment of Persistent Corneal Epithelial Defects
Role: lead
Study of ST266 Given by Intranasal Delivery in Glaucoma Suspect Subjects
Role: lead
Safety and Tolerability Study of IV ST266 in COVID-19 Subjects
Role: lead
ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects
Role: lead
Safety, Efficacy and Treatment Regimen Study of ST266 in Subjects With Moderate to Severe Periodontitis
Role: lead
ST266 in UV-induced Inflammation
Role: lead
ST266 Versus Standard Care In Treating Partial Thickness Burns
Role: lead
Study of ST266 in Diabetic Subjects With Deep Burns Managed With Skin Grafts
Role: lead
Study of ST266 Versus Saline in Treating Skin Irritation From Radiation
Role: lead
Study of ST266 Eye Drops in Treating Dry Eye
Role: lead
Treatment of Human Gingivitis With Amnion-derived Cellular Cytokine Solution (ACCS)
Role: lead
All 13 trials loaded